Cancer Letters
Volume 291, Issue 2 , Pages 209-216 , 28 May 2010

Repeated hepatocyte growth factor neutralizing antibody treatment leads to HGF/SF unresponsiveness in human glioblastoma multiforme cells

  • Ping Zhao

      Affiliations

    • Nanjing Medical University Cancer Center, Key Laboratory of Antibody Technology of Ministry of Health, Nanjing, China
    • Van Andel Research Institute, Grand Rapids, MI, USA
    • ,
  • Chongfeng Gao

      Affiliations

    • Van Andel Research Institute, Grand Rapids, MI, USA
    • ,
  • Karl Dykema

      Affiliations

    • Van Andel Research Institute, Grand Rapids, MI, USA
    • ,
  • Kyle Furge

      Affiliations

    • Van Andel Research Institute, Grand Rapids, MI, USA
    • ,
  • Zhenqing Feng

      Affiliations

    • Nanjing Medical University Cancer Center, Key Laboratory of Antibody Technology of Ministry of Health, Nanjing, China
    • Corresponding Author InformationCorresponding authors. Addresses: Van Andel Institute, 333 Bostwick Ave., NE, Grand, Rapids, MI 49503, USA. Tel.: +1 616 234 5342; fax: +1 616 234 5343 (B. Cao), Department of Pathology, Nanjing Medical University, 140 Hanzhong Road, Nanjing, Jiangsu 210029, China. Tel.: +86 25 8686 2011 (Z. Feng).
    • ,
  • Brian Cao

      Affiliations

    • Nanjing Medical University Cancer Center, Key Laboratory of Antibody Technology of Ministry of Health, Nanjing, China
    • Van Andel Research Institute, Grand Rapids, MI, USA
    • Corresponding Author InformationCorresponding authors. Addresses: Van Andel Institute, 333 Bostwick Ave., NE, Grand, Rapids, MI 49503, USA. Tel.: +1 616 234 5342; fax: +1 616 234 5343 (B. Cao), Department of Pathology, Nanjing Medical University, 140 Hanzhong Road, Nanjing, Jiangsu 210029, China. Tel.: +86 25 8686 2011 (Z. Feng).

Received 16 July 2009 ,Revised 9 October 2009 ,Accepted 19 October 2009.

References 

  1. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer. 2002;2(4):289–300
  2. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003;4(12):915–925
  3. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251:802–804
  4. Rubin JS, Bottaro DP, Aaronson SA. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochem. Biophys. Acta. 1993;1155:357–371
  5. Tsarfaty I, Rong S, Resau JH, Shen R, Pedro Pinto DS, Vande Woude GF. The met proto-oncogene in mesenchymal to epithelial cell conversion. Science. 1994;263:98–101
  6. Montesano R, Matsumoto K, Nakamura T, Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell. 1991;67:901–908
  7. Tsarfaty I, Resau JH, Rulong S, Keydar I, Faletto DL, Vande Woude GF. The met proto-oncogene receptor and lumen formation. Science. 1992;257:1258–1261
  8. Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis. Biochem. Biophys. Res. Commun. 1999;255:80–87
  9. Schmidt N, Westphal M, Hagel C, Ergun S, Stavrou D, Rosen E, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer. 1999;84:10–18
  10. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 1997;57:5391–5398
  11. Laterra J, Nam M, Rosen E, Rao JS, Lamszus K, Goldberg ID, et al. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest. 1997;76(4):565–577
  12. Cao B, Su Y, Oskarsson M, Zhao P, Kort E, Fisher RJ, et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA. 2001;98:7443–7448
  13. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6:401–410
  14. Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin. Proc. 2006;81(6):758–767
  15. Sakata H, Stahl SJ, Taylor WG, Rosenberg JM, Sakaguchi K, Wingfield PT, et al. Heparin binding and oligomerization of hepatocyte growth factor/scatter factor isoforms. J. Biol. Chem. 1997;272:9457–9463
  16. Rong S, Oskarsson M, Faletto D, et al. Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human Met protooncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ. 1993;4:563–569
  17. Jeffers M, Rong S, Vande Woude GF. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signaling in human cells concomitant with induction of the urokinase proteolysis network. Mol. Cell Biol. 1996;16:1115–1125
  18. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc. Natl. Acad. Sci. USA. 2005;102(16):5814–5819
  19. Buie LW, Valgus J. Bevacizumab: a treatment option for recurrent glioblastoma multiforme. Ann. Pharmacother. 2008;42(10):1486–1490
  20. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 2008;14:6735–6741
  21. Huang S, Mills L, Mian B, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 2002;161:125–134
  22. Mian B, Dinney C, Bermejo C, et al. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-κB. Clin. Cancer Res. 2003;9:3167–3175
  23. Ren Y, Cao B, Law S, et al. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin. Cancer Res. 2005;11:6190–6197

PII: S0304-3835(09)00636-3

doi: 10.1016/j.canlet.2009.10.014

Cancer Letters
Volume 291, Issue 2 , Pages 209-216 , 28 May 2010

Article Tools

* Image Usage & Resolution